why choose us

First received: February 21, 2023

Clinical Trial: Allo HSCT Using RIC and PTCy for Hematological Diseases

Study Status: Completed

Recruit Status: RECRUITING

Condition: Acute Myelogenous Leukemia

Study Type: INTERVENTIONAL


Official Title: Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Brief Summary: This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.

Read more